Efavirenz Patent Expiration

Efavirenz is used for managing HIV infection in combination with other antiviral drugs. It was first introduced by Bristol Myers Squibb Co in its drug Sustiva on Sep 17, 1998. 9 different companies have introduced drugs containing Efavirenz.


Efavirenz Patents

Given below is the list of patents protecting Efavirenz, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sustiva US6238695

(Pediatric)

Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants Oct 06, 2019

(Expired)

Bristol Myers Squibb
Sustiva US6555133

(Pediatric)

Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants Oct 06, 2019

(Expired)

Bristol Myers Squibb
Sustiva US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants Apr 06, 2019

(Expired)

Bristol Myers Squibb
Sustiva US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants Apr 06, 2019

(Expired)

Bristol Myers Squibb
Sustiva US6639071

(Pediatric)

Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one Aug 14, 2018

(Expired)

Bristol Myers Squibb
Sustiva US6939964

(Pediatric)

Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one Jul 20, 2018

(Expired)

Bristol Myers Squibb
Sustiva US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one Feb 14, 2018

(Expired)

Bristol Myers Squibb
Sustiva US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one Jan 20, 2018

(Expired)

Bristol Myers Squibb
Sustiva US5663169

(Pediatric)

Benzoxazinones as inhibitors of HIV reverse transcriptase Mar 02, 2015

(Expired)

Bristol Myers Squibb
Sustiva US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase Sep 02, 2014

(Expired)

Bristol Myers Squibb
Sustiva US5519021

(Pediatric)

Benzoxazinones as inhibitors of HIV reverse transcriptase Nov 21, 2013

(Expired)

Bristol Myers Squibb
Sustiva US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase May 21, 2013

(Expired)

Bristol Myers Squibb
Sustiva US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase Aug 07, 2012

(Expired)

Bristol Myers Squibb



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Efavirenz's patents.

Given below is the list recent legal activities going on the following patents of Efavirenz.

Activity Date Patent Number
Patent litigations
Patent Issue Date Used in PTA Calculation 29 Apr, 2003 US6555133
Recordation of Patent Grant Mailed 29 Apr, 2003 US6555133
Issue Notification Mailed 10 Apr, 2003 US6555133
Receipt into Pubs 14 Mar, 2003 US6555133
Receipt into Pubs 06 Mar, 2003 US6555133
Receipt into Pubs 03 Mar, 2003 US6555133
Application Is Considered Ready for Issue 28 Feb, 2003 US6555133
Issue Fee Payment Received 19 Feb, 2003 US6555133
Issue Fee Payment Verified 19 Feb, 2003 US6555133
Receipt into Pubs 11 Feb, 2003 US6555133


Efavirenz's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Efavirenz Generic API Manufacturers

Several generic applications have been filed for Efavirenz. The first generic version for Efavirenz was by Mylan Pharmaceuticals Inc and was approved on Feb 17, 2016. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on May 10, 2024.

Given below is the list of companies who have filed for Efavirenz generic, along with the locations of their manufacturing plants worldwide.